Cellectis SA Company Profile (NASDAQ:CLLS)

Analyst Ratings

Consensus Ratings for Cellectis SA (NASDAQ:CLLS) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $47.25 (81.03% upside)

Analysts' Ratings History for Cellectis SA (NASDAQ:CLLS)
Show:
DateFirmActionRatingPrice TargetActions
7/27/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016Ladenburg ThalmannInitiated CoverageBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016SunTrust Banks Inc.Initiated CoverageBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015Bank of America Corp.Initiated CoverageBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2015Jefferies GroupInitiated CoverageBuy$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Cellectis SA (NASDAQ:CLLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/12/2016Q116($0.35)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2016Q415($0.30)$0.65ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/19/2015Q215($0.43)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cellectis SA (NASDAQ:CLLS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.56)($0.43)($0.50)
Q2 20163($0.65)($0.44)($0.55)
Q3 20163($0.65)($0.45)($0.56)
Q4 20163($0.65)($0.46)($0.57)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cellectis SA (NASDAQ:CLLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cellectis SA (NASDAQ:CLLS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Cellectis SA (NASDAQ:CLLS)
DateHeadline
07/23/16 07:33 AMImportance Of Phase 1 Trials - Benzinga
07/22/16 01:18 PMImportance Of Phase 1 Trials -
07/21/16 12:53 PMETF’s with exposure to Cellectis SA : July 21, 2016 -
07/20/16 10:56 AMBroker Outlook For Cellectis S.A. (CLLS) - Fiscal Standard
07/17/16 07:52 AMNext Weeks Broker Price Targets For Cellectis S.A. (CLLS) - Fiscal Standard
07/15/16 02:20 PMNew Broker Ratings For Cellectis S.A. (CLLS) - FTSE News
07/13/16 03:22 PMJuno Therapeutics Soars 25% After ROCKET Phase 2 Rocket Trial Resumption - Benzinga
07/13/16 03:22 PMCellectis SA (ADR) Can't Be More Safe. Trades Significantly Higher - Consumer Eagle
07/13/16 03:22 PMCellectis S.A. (CLLS) Current Analyst Ratings - Fiscal Standard
07/13/16 09:34 AMJuno Therapeutics Stock Spikes After Cancer Trial Resumes -
07/12/16 07:29 AMMoving Stocks: Cellectis S.A. (NASDAQ:CLLS), 3M Company (NYSE:MMM), Telefonaktiebolaget LM Ericsson ... - KC Register
07/06/16 03:22 PMCellectis S.A. (NASDAQ:CLLS) Rose 2.48%: Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR), Liberty Tax, Inc ... - KC Register
06/30/16 03:29 PMRecently Issued Stock Ratings For Cellectis S.A. (CLLS) - Fiscal Standard
06/27/16 04:41 PMMIT Technology Review Names Cellectis on Annual List of 50 Smartest Companies for Second Consecutive Year - [at noodls] - 00669732-955c-42ec-a990-8d5059f359fd.pdf PRESS RELEASE MIT Technology Review Names Cellectis on Annual List of 50 Smartest Companies for Second Consecutive Year June 27, 2016 - New York (USA) - Cellectis ...
06/27/16 04:41 PMCellectis Named 2016 Technology Pioneer by the World Economic Forum - [at noodls] - Cellectis' selection was based on its contribution to and impact on the global healthcare and life sciences industries via the Company's development and therapeutic application of allogeneic CAR T-cell ...
06/27/16 03:12 PMCellectis SA Ads (NASDAQ:CLLS) Shorted Shares Decreased By 12.67% - Engelwood Daily
06/27/16 03:12 PMCellectis S.A. (CLLS) Broker Price Targets For The Coming Week - Fiscal Standard
06/23/16 10:35 PMCellectis S.A. (CLLS) Updated Price Targets - FTSE News
06/20/16 04:59 PMCellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL) - [at noodls] - e6e9713c-2a4a-4dd8-96d1-0ed783d1afea.pdf PRESS RELEASE New York, N.Y. - June 20, 2016 - Cellectis (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based ...
06/20/16 01:13 PMETF’s with exposure to Cellectis SA : June 20, 2016 -
06/13/16 02:42 PMEarnings to Watch: Digital Turbine, Inc. (NASDAQ:APPS), Cellectis S.A. (NASDAQ:CLLS), MV Oil Trust (NYSE:MVO ... - KC Register
06/05/16 11:03 AMAfter Last Week What Do Analysts Think Of Cellectis S.A. (CLLS) - Share Trading News
06/04/16 11:49 AMCellectis SA's (CLLS) “Buy” Rating Reaffirmed at Oppenheimer - Let Me Know About This
06/03/16 03:25 PMBuy, Sell Or Hold Rating For Cellectis S.A. (CLLS)? - Share Trading News
06/03/16 02:13 PMETF’s with exposure to Cellectis SA : June 3, 2016 -
06/01/16 03:23 PMCellectis S.A. (CLLS) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Cellectis S.A. (CLLS) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Cellectis S.A. (CLLS). The latest reports which are currently in issue on Wednesday 1st of June state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...and more »
06/01/16 11:49 AMCellectis SA :CLLS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/30/16 10:41 PMCellectis SA (CLLS) Earns Buy Rating from Piper Jaffray - Let Me Know About This - Cellectis SA (CLLS) Earns Buy Rating from Piper JaffrayLet Me Know About ThisCellectis SA logo Cellectis SA (NASDAQ:CLLS)'s stock had its “buy” rating reaffirmed by equities researchers at Piper Jaffray in a report issued on Sunday. Cellectis SA (NASDAQ:CLLS) traded down 1.55% during mid-day trading on Friday, hitting $31.22.Next Weeks Broker Price Targets For Cellectis S.A. (CLLS)Share Trading Newsall 2 news articles »
05/30/16 12:34 PMNext Weeks Broker Price Targets For Cellectis S.A. (CLLS) - Share Trading News - Next Weeks Broker Price Targets For Cellectis S.A. (CLLS)Share Trading News03/02/2016 – SunTrust began new coverage on Cellectis S.A. giving the company a “buy” rating. They now have a USD 35 price target on the stock. 02/29/2016 – Cellectis S.A. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have ...
05/23/16 04:00 PMCalyxt Appoints Federico A. Tripodi to New Role of CEO - [Business Wire] - Calyxt, Inc., a Minnesota-based company developing healthier food products to benefit both consumers and growers, announced today the appointment of former Monsanto Corporation executive Federico A.
05/19/16 05:02 PMCellectis S.A. Reports Results from Shareholders’ General Meeting Held on May 17, 2016 - [at noodls] - 1715839e-ddad-4234-8e8d-c6b078c8d7f9.pdf PRESS RELEASE Cellectis S.A. Reports Results from Shareholders' General Meeting Held on May 17, 2016 New York, May 19, 2016 - Cellectis S.A. Shareholders' General ...
05/11/16 06:07 PMCellectis Reports First Quarter 2016 Financial Results - [at noodls] - d62cf528-78f9-4bce-9f3d-982fa52c9cc9.pdf PRESS RELEASE - Initiated UCART123 GMP production concept - Secured strategic supply of key materials for GMP manufacturing - Strong cash position of $315 million ...
05/11/16 06:07 PMFirst Quarter 2016 Financial Results - [at noodls] - 9d972143-29b0-4be7-a78a-93219d79d119.pdf UNITED STATES‌ SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities ...
05/09/16 05:41 AMCellectis' gene editing breakthrough: CEO -
05/06/16 07:14 PMAACR Posters 2016 - [at noodls] - 434b933e-e077-4871-be48-dcab847424ef.pdf Allogeneic TCR/CS1 double knockout T-­‐cells bearing an an9-­‐CS1 chimeric an9gen receptor: An improved immunotherapy approach for the treatment of Mul9ple Myeloma ...
05/06/16 06:14 PMASGCT Posters 2016 - [at noodls] - debc7ab4-ac00-403f-b90a-eeb3313718c7.pdf u Integra0on of Dual Signal Input Strategies in Novel Chimeric An0gen Receptors to Control the CAR T-­‐Cell Func0ons Alexandre Juillerat, Alan Marechal, Jean Marie ...
05/02/16 04:20 PMCellectis to Present Data on its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting - [at noodls] - ac67e175-7d36-415d-84e5-4d4a51a6d18a.pdf PRESS RELEASE Cellectis to Present Data on its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting May the 2nd, 2016 ...
04/28/16 11:24 AMConsolidated financial statements - Year ended December 31, 2015 - [at noodls] - b9cf3604-3b4d-401e-a4ae-aa1e9ec55ff8.pdf JMH CONSEIL ERNST & YOUNG et Autres This is a free translation into English of the statutor y auditors' report on the consolidated financial statements issued in ...
03/25/16 12:04 PMCELLECTIS S.A. Financials -
03/21/16 04:54 PMCellectis Announces RetroNectin® Supply and License Agreement with Takara Bio Inc. - [at noodls] - 58639e23-5605-4c42-bb08-d43737ae9f48.pdf PRESS RELEASE New York, March 21, 2016 - Cellectis (Alternext: ALCLS - Nasdaq Global Market: CLLS), a biopharmaceutical company focused on developing immunotherapies ...
03/02/16 01:48 PMCellectis SA (ADR) (CLLS) is Initiated by Sun Trust Rbsn Humphrey to Buy - Los Angeles Mirror - Cellectis SA (ADR) (CLLS) is Initiated by Sun Trust Rbsn Humphrey to BuyLos Angeles MirrorCellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research development and commercialization of rational genome engineering technologies. It has developed an ...and more »
03/02/16 06:41 AMCoverage initiated on Cellectis by Sun Trust Rbsn Humphrey -
03/01/16 08:00 PMCellectis Subsidiary Calyxt, Acquires Land for New Headquarters Facility - [Business Wire] - Regulatory News:
02/28/16 01:19 PMCellectis SA Ads (NASDAQ:CLLS) Sellers Increased By 11.35% Their Shorts - Business Standard Tribune - Cellectis SA Ads (NASDAQ:CLLS) Sellers Increased By 11.35% Their ShortsBusiness Standard TribuneThe stock of Cellectis SA Ads (NASDAQ:CLLS) registered an increase of 11.35% in short interest. CLLS's total short interest was 1.39M shares in February as published by FINRA. Its up 11.35% from 1.25 million shares, reported previously. With 155,800 ...
02/24/16 01:47 PMCellectis SA Ads (NASDAQ:CLLS) Shorts Decreased by 2.07% After Short Covering - Clinton Financial - Cellectis SA Ads (NASDAQ:CLLS) Shorts Decreased by 2.07% After Short CoveringClinton FinancialThe stock of Cellectis SA Ads (NASDAQ:CLLS) registered a decrease of 2.07% in short interest. CLLS's total short interest was 1.25 million shares in February as published by FINRA. Its down 2.07% from 1.28M shares, reported previously. With 176,700 ...
02/22/16 01:26 PMUpdated Price Targets On Cellectis S.A. (CLLS) - Risers & Fallers - Updated Price Targets On Cellectis S.A. (CLLS)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Cellectis S.A. (CLLS). The latest broker reports which are currently outstanding on Monday 22nd of February state 3 analysts have a rating of “strong buy”, 1 analysts “buy ...Zacks: Brokerages Set $56.00 Price Target for Cellectis SA (NASDAQ:CLLS)Financial Market NewsStock Highlights: Cellectis S.A. (NASDAQ:CLLS), Graphic Packaging Holding Company (NYSE:GPK), Stage Stores ...KC Registerall 3 news articles »
02/18/16 01:22 PMCellectis SA (ADR) (NASDAQ:CLLS) announced that it entered into a new agreement for the cGMP manufacturing of ... - Inside Trade - Cellectis SA (ADR) (NASDAQ:CLLS) announced that it entered into a new agreement for the cGMP manufacturing of ...Inside TradeCellectis SA (ADR) (NASDAQ:CLLS) announced that it entered into a new agreement for the cGMP manufacturing of UCART123 clinical batches, Cellectis' lead product candidate, with CELLforCURE, an LFB group company and the largest industrial facility ...
02/16/16 01:35 PMCellectis SA (ADR) (CLLS) Stock Surges 18% – Why is this stock up so much? - Independent Reporter - Cellectis SA (ADR) (CLLS) Stock Surges 18% – Why is this stock up so much?Independent ReporterShares of Cellectis SA (ADR) (NASDAQ:CLLS) have jumped 18.25% to $23.00 in pre-market trading this morning, even though the company did not release any news. Specializing in creating T-cells which have memories that allow them to attack cancer cells ...Cellectis Up More Than 19% As Director And Other Business Entities Acquire 3.3 Million Shares, 9.42% Stake ...WallStreet.orgall 2 news articles »
02/13/16 01:31 PMCellectis SA Ads (NASDAQ:CLLS) Sellers Covered 2.07% of Their Shorts - fdanewsalert.com - Cellectis SA Ads (NASDAQ:CLLS) Sellers Covered 2.07% of Their Shortsfdanewsalert.comThe stock of Cellectis SA Ads (NASDAQ:CLLS) registered a decrease of 2.07% in short interest. CLLS's total short interest was 1.25M shares in February as published by FINRA. Its down 2.07% from 1.28M shares, reported previously. With 176,700 shares ...
02/11/16 01:31 PMLatest Analysts Reports On Cellectis S.A. (CLLS) - Risers & Fallers - Latest Analysts Reports On Cellectis S.A. (CLLS)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Cellectis S.A. (CLLS). The latest broker reports which have been released state 3 analysts have a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, 0 analysts ...

Social

About Cellectis SA

Cellectis SA logoCellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLLS
  • CUSIP:
Key Metrics:
  • Previous Close: $26.01
  • 50 Day Moving Average: $26.64
  • 200 Day Moving Average: $26.58
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $919.45M
  • Beta: 2.23
  • Current Year EPS Consensus Estimate: $-1.71 EPS
  • Next Year EPS Consensus Estimate: $-1.93 EPS
Additional Links:
Cellectis SA (NASDAQ:CLLS) Chart for Friday, July, 29, 2016